Array BioPharma Inc. (NASDAQ:ARRY) registered a -5.18% decrease, still its new closing price is 345.80% up from the company’s 1 year high of 11.65.It posted -5.10% losses in previous 5 sessions and is now the subject of 0 analysts who together assign a hold rating on stock. 0 of Wall Street analysts have an underperform rating; the 0 sells versus 4 buy or better ratings. The 9 stock analysts following this company have an average price target at $11.00, with individual PT in the $8.00-$15.00 range. The shares moved at $10.61, implying that brokerage firms see shares gaining about 243.37% in twelve months time.
Array BioPharma Inc. (ARRY) SEC Form 4 News
The stock is getting much attention these days as insiders are offloading shares while they posted a 20.71% rise year to date. A 10% Owner at Array BioPharma Inc. (ARRY) offloaded shares in a transaction closed on Wednesday September 28, 2016. Redmile Group, LLC sold 2,492,578 shares in the company at $6.36 each and collected $15,852,001 in proceeds. Redmile Group, LLC now owns 16,658,072 shares in the company after this transaction. A 10% Owner in the company, Redmile Group, LLC, disclosed a transaction on Thursday September 15, 2016 that ended up generating $1,400,000 from the sale of 400,000 shares at $3.5 per share.
Array BioPharma Inc. (NASDAQ:ARRY) Upcoming Results on Tap
Array BioPharma Inc. will next provide financial results for the September 2017 quarter. Stock analysts expect it to report per-share earnings of $-0.14 in that period. Sales during the quarter are predicted to arrive at $27.5 million.
Earnings surprise history: Last quarter, the company posted approximately $39.27 million in revenue and EPS of $-0.20. The mean forecast was for $32.47 million and $-0.16 a share, respectively. One quarter earlier, revenue for the stock was at $43.21 million, with earnings at $-0.17/share.
Array BioPharma Inc. (ARRY) Brokerage Update
Array BioPharma Inc. (ARRY) is in Leerink Partners’s research list so their analyst rating change is noteworthy. These shares were downgraded to Mkt Perform from Outperform by Leerink Partners, according to news reported on Monday January 30, 2017.Another important research note was issued by UBS on Friday July 23, 2010.The firm upgraded ARRY to Buy from Neutral. Over the last six months and over the last three months, the shares of Array BioPharma Inc. (ARRY), have changed 183.69% and 78.32%, respectively.